BioNTech to Close Three German Manufacturing Sites as COVID Vaccine Demand Collapses and Oncology Pivot Accelerates

What happened

BioNTech, the Mainz-based company that became a household name through its COVID-19 vaccine, announced on Monday, September 28, 2026, that it will close three German manufacturing sites, Marburg, Idar-Oberstein and Tübingen, after a "wide-ranging sales process" failed to find buyers for them. A company spokesperson said: "Despite the best efforts of all those involved and a wide-ranging sales process, it has unfortunately not been possible to finalise a sale," according to 24ur.com. The three German closures alone affect around 1,800 employees, and the broader manufacturing-network consolidation program, first announced in May 2026, could affect up to approximately 1,860 jobs. BioNTech has reached agreements with its works council on supplementary redundancy terms for affected workers, and the company says the consolidation will not affect commercial or clinical supply or contractual obligations.

The closures are the consequence of a demand collapse for COVID-19 vaccines that has left the company with far more manufacturing capacity than its current order book requires. The Marburg site carries particular symbolic weight: BioNTech bought it from Novartis in 2020 to scale up pandemic vaccine production, at the time projecting it could produce up to 750 million vaccine doses per year at full capacity, and it took on roughly 300 employees with the acquisition. The Singapore site, also acquired from Novartis, in 2022, is slated to cease operations in the first quarter of 2027; BioNTech had sought a buyer for that facility as well, without success. Closure timelines for the German sites differ: Tübingen by the end of 2027, Marburg in early 2028, and Idar-Oberstein by the end of 2028, per Fierce Pharma data cited by 24ur.com.

The financial backdrop explains the move. In the first quarter of 2026, BioNTech recorded €118.1 million in revenue, down from €182.8 million in the first quarter of 2025, and posted a net loss of €531.9 million, which the company attributed mainly to lower COVID-19 vaccine revenues. Research and development spending in the quarter was €557 million, higher year-over-year, driven by immuno-oncology and antibody-drug conjugate programs. The restructuring is expected to generate recurring annual savings of approximately €500 million, about $587 million, once fully implemented by 2029, with resources redirected toward the company's oncology pipeline. BioNTech has said it aims to become a multi-product biopharmaceutical company by 2030, focused on cancer immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies.

Not every divestment attempt failed. In August, BioNTech agreed to sell all shares in JPT Peptide Technologies to a fund advised by Munich-based DUBAG. Separately, and beyond the restructuring itself, the company's two co-founders plan to depart by year-end to launch a new venture, a signal of a broader leadership transition at the firm, per the Ground News AI summary of the coverage.

Why it matters

The decision marks the definitive end of the pandemic-era buildout for one of the two companies that defined mRNA vaccine production. Marburg was acquired at the peak of the crisis with a projected capacity of up to 750 million doses per year; four years later, no buyer could be found for it, and quarterly revenue has fallen to €118.1 million against a €531.9 million net loss. The roughly 1,800 employees affected at the three German sites represent the human dimension of that reversal, in a country where manufacturing employment carries particular political weight.

The restructuring also clarifies BioNTech's strategic direction. With R&D spending of €557 million in a single quarter, exceeding quarterly revenue several times over, the company is funding its oncology pivot through cost cuts elsewhere. The targeted €500 million in recurring annual savings by 2029 is the financial bridge to that strategy, and the planned departure of both co-founders by year-end adds a leadership dimension to what is already a structural transformation. Whether the consolidation proceeds without disrupting commercial or clinical supply, as the company asserts, is the operational question that follows.

How it is being covered

According to ground.news, the story is carried by 102 sources, of which 33 have been rated, with a left/centre/right split of 15/36/49 percent and 26 of the 33 rated outlets showing high or very high factuality. Coverage skews toward the right of the political spectrum, and outlets such as LifeZette have framed the story around falling vaccine demand at the top mRNA vaccine maker. Ground News flags no blindspot on the story, meaning no significant partisan segment is missing from the coverage.

What to watch

Three things merit attention in the coming months. First, the Singapore wind-down in the first quarter of 2027, the earliest of the announced closures, will show how the timeline holds in practice. Second, the year-end departure of the two co-founders and the launch of their new venture will clarify how much institutional knowledge and leadership continuity the company retains through the transition. Third, quarterly results through 2027 will indicate whether the oncology pipeline and the €500 million savings target are closing the gap left by collapsing COVID-19 vaccine revenues, and whether further capacity reductions follow if they do not.

By the numbers

Source snapshot